Tracking 6 vendors · 83 listings · checked Aug 02Current partner codePEPTIDESDE

ApprovedWeight lossSubcutaneousEvidence 5/5

Liraglutide

Also known as: Victoza, Saxenda

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Read full research guide View clinical trials Buy / compare source

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative profileSubcutaneous

Database profileApproved

LiraglutideWeight loss

Drug class: GLP-1 receptor agonist
Primary targets: GLP-1R
Dose reference: 0.6–3.0 mg once daily
Half-life: ~13 hours
Developer / origin: Novo Nordisk
Reference year: 2010
Evidence score: 5/5 - Approved with human RCTs

Approved uses

Type 2 diabetes
Chronic weight management

Evidence 5/5

Approved with human RCTs

Liraglutide has randomized weight-management trial data and FDA-regulated labeling for approved diabetes and obesity indications.

Approved medication with substantial human clinical evidence.

Evidence basis

Human RCTs
FDA-regulated labeling
Approved GLP-1 receptor agonist

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Liraglutide guides

Read the matching guide or adjacent research pages for more context.

Saxenda (Liraglutide): The Original Weight-Loss GLP-1 (2026)Saxenda (liraglutide) was the first GLP-1 approved for weight management. Daily injection, ~8% average weight loss, and still a useful option when newer weekly drugs aren't accessible.Novo Nordisk's GLP-1 Lineup: Ozempic, Wegovy, Rybelsus, Saxenda (2026)Novo Nordisk pioneered the modern GLP-1 era with semaglutide and liraglutide. In 2026 the lineup is Ozempic, Wegovy, Rybelsus, Saxenda, oral Wegovy, and the Phase 3 CagriSema combination.FDA-Approved GLP-1 Drugs for Weight Loss in 2026Five GLP-1 medications are FDA-approved for chronic weight management in 2026. Wegovy, Zepbound and Saxenda by injection; oral Wegovy and Foundayo by pill — with approval dates for each.GLP-1 Dosage for Weight Loss: Schedules for Every Approved Drug (2026)GLP-1 weight-loss dosing follows a slow titration pattern. Every approved drug's dose schedule — Wegovy, Zepbound, Saxenda, oral Wegovy and Foundayo — with the titration tables prescribers follow.

Liraglutide calculator shortcuts

Open peptide calculators with editable Liraglutide example values already filled in.

Liraglutide accumulation calculatorPrefills 13 hour half-life and 24 hour interval examples.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open tool Peptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open tool Peptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open tool Peptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5

Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5

Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5

Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Cagrilintide

AM833

4/5

Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →